Inclusion Criteria:

1. Histologically proven colon cancer stage Dukes' C.

2. Patient over 18 years.

3. WHO performance status <1.

4. Adequate haematological function (Hb ≥ 100 g/L, ANC ≥ 2.0 x 109/L, platelets ≥ 150 x
109/L)

5. Adequate renal and hepatic functions: serum creatinine and total bilirubin ≤ 1.25
times upper normal limits (ASAT and ALAT ≤ 3 times upper normal limits)

6. Clinical evaluation, haematology and biochemistry performed within 1 week prior to
the start of chemotherapy

7. Use of adequate contraception (males with reproductive potential)

8. Written informed consent given

Exclusion Criteria:

1. Other tumour types than colon adenocarcinomas

2. Current severe neutropenia, leucopenia or thrombocytopenia

3. Severely reduced liver or renal function

4. Unresolved bowel obstruction or sub-obstruction, uncontrolled Crohn's disease or
ulcerative colitis

5. Current chronic diarrhoea

6. Contraindication for corticosteroid administration

7. History of prior serious allergic or pseudo-allergic reaction

8. Any other serious illness or medical condition

9. Symptomatic peripheral neuropathy ≥ grade 2

10. Received mangafodipir ≤ 5 weeks before planned start of chemotherapy

11. Received any of the FOLFOX drugs ≤ 5 weeks before planned start of chemotherapy

12. Any plans of administered other anti-cancer therapy (including radiotherapy)
concurrent with this study

13. Fertile females

14. Males with reproductive potential not implementing adequate contraception measures

15. Phaeochromocytoma